(Q39702824)

English

High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

author name string

Xiaoyan Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Huaijun Tu

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Yazhi Yang

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Qian Wan

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Lijun Fang

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Qiong Wu

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Jian Li

7

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

358-367

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Advances in understanding the leukaemia microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: key role of stromal microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

IL-7 in human health and disease

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-2028-9

21 January 2018

Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27272942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27272942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/27272942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/27272942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/27272942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/27272942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-016-2028-9

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39702824&oldid=2203107108"